Sugi Predict

Sugi Predict / Compounds / SCHEMBL4745237

SCHEMBL4745237

SCHEMBL4745237

COC(=O)[C@H](CO[Si](C)(C)C(C)(C)C)NC(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 10/20 0.41
▸ CTSS P25774 7/20 0.41
▸ CTSL P07711 3/20 0.41
▸ CTSB P07858 1/20 0.41
▸ GSTP1 P09211 1/20 0.40
▸ GSTM2 P28161 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ NFKB1 P19838 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ KLK5 Q9Y337 1/20 0.38
▸ CAPN1 P07384 1/20 0.36
▸ PPARA Q07869 1/20 0.36
▸ CA12 O43570 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3617063 1.00 CTSK (0.41) CTSKCTSSCTSLCTSBGSTP1
SCHEMBL3617062 1.00 CTSK (0.41) CTSKCTSSCTSLCTSBGSTP1
SCHEMBL9691674 0.90 CTSK (0.40) CTSKCTSSCTSLCTSBCYP1A2
SCHEMBL2479841 0.88 CTSK (0.40) CTSKCTSSCTSLCTSBGSTP1
SCHEMBL7991202 0.87 PPARA (0.48) CTSKCTSSCTSLCTSBCA1
SCHEMBL4388129 0.87 PPARA (0.48) CTSKCTSSCTSLCTSBCA1
SCHEMBL15129729 0.87 PPARA (0.48) CTSKCTSSCTSLCTSBCA1
SCHEMBL19661550 0.86 CYP1A2 (0.42) CTSKCTSSCTSLCTSBCYP1A2
SCHEMBL23177271 0.86 CTSK (0.42) CTSKCTSSCTSLCTSBGSTP1
SCHEMBL17271823 0.86 CTSK (0.42) CTSKCTSSCTSLCTSBGSTP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105254589-B A method of preparing heart failure drugs intermediate 上海博氏医药科技有限公司 2018-07-31 — — CN claimed
CN-105254589-A Method for preparing midbody of heart failure medicine SHANGHAI BOSHI PHARMACEUTICAL CO LTD 2016-01-20 — — CN claimed
US-20250353848-A1 HETEROCYCLIC PAD4 INHIBITORS CELGENE CORPORATION 2025-11-20 — — US disclosed
US-20250346592-A1 HETEROCYCLIC PAD4 INHIBITORS CELGENE CORPORATION 2025-11-13 — — US disclosed
US-12384797-B2 Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia PTC THERAPEUTICS, INC. (US) 2025-08-12 — — US disclosed
WO-2025137639-A1 MIXED SEROTONIN RECEPTOR BINDERS FOR TREATMENT OF PSYCHOTIC DISORDERS DELIX THERAPEUTICS, INC. (US) 2025-06-26 — — WO disclosed
US-20250171420-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS AG (CH) 2025-05-29 — — US disclosed
EP-4540240-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME Monte Rosa Therapeutics AG (CH) 2025-04-23 — — EP disclosed
EP-4531849-A1 HETEROCYCLIC PAD4 INHIBITORS CELGENE CORPORATION (US) 2025-04-09 — — EP disclosed
WO-2023244815-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS, INC. (US) 2023-12-21 — — WO disclosed
WO-2023230612-A1 HETEROCYCLIC PAD4 INHIBITORS CELGENE CORPORATION (US) 2023-11-30 — — WO disclosed
CN-105254589-A Method for preparing midbody of heart failure medicine SHANGHAI BOSHI PHARMACEUTICAL CO LTD 2016-01-20 — — CN disclosed
US-20080293712-A1 Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof WYETH (US) 2008-11-27 — — US disclosed
WO-2008109613-A1 BENZO[C][2,7]NAPHTHYRIDINE DERIVATIVES, AND THEIR USE AS KINASE INHIBITORS WYETH (US) 2008-09-12 — — WO disclosed
EP-1310482-A1 Prodrugs of excitatory amino acids ELI LILLY AND COMPANY (US) 2003-05-14 — — EP disclosed
EP-0723545-B1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LAB (US) 2002-05-08 — — EP disclosed
US-5726182-A TREATMENT OF BACTERIAL INFECTIONS ABBOTT LABORATORIES (US) 1998-03-10 — — US disclosed
US-5599816-A BACTERICIDE ABBOTT LABORATORIES (US) 1997-02-04 — — US disclosed
US-5580872-A ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS ABBOTT LABORATORIES (US) 1996-12-03 — — US disclosed
WO-1995010519-A1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LABORATORIES (US) 1995-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353848-A1 HETEROCYCLIC PAD4 INHIBITORS PADI4, PADI1, PADI6 CTSK 3722/4885CTSS 3696/4885CTSL 3903/4885
US-12384797-B2 Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia SF3B5, SF3B2, SF3B1 CTSK 4597/4885CTSS 4459/4885CTSL 4757/4885
US-20250171420-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME PSMA1, CSNK1G1, CSNK1A1 CTSK 59/4885CTSS 193/4885CTSL 862/4885
US-20250346592-A1 HETEROCYCLIC PAD4 INHIBITORS PADI4, PADI6, PADI2 CTSK 4092/4885CTSS 4137/4885CTSL 4243/4885
US-20080293712-A1 Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof PDPK1, PDK2, PDK3 CTSK 551/4885CTSS 2964/4885CTSL 4101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.